Orlistat predominantly has activity against FASN expressed in the cells of the gut, and acts to reduce dietary fat uptake, hence its applications to the treatment of obesity.[42] However, some orlistat is available systemically [43, 44], suggesting possible application in anti-DENV therapy. The gene discussed is FASN; the disease is obesity disorder.